At least five biopharma companies have filed paperwork with the US Securities and Exchange Commission (SEC) since the start of 2024 to signal their intention to go public this year, entering what still is a largely inhospitable market despite the recent rise in drug developer stock prices. However, the two most recent form S-1 filers – Kyverna Therapeutics and Alto Neuroscience – may fall right into initial public offering investors’ sweet spot for new IPOs.
Finance Watch: Kyverna, Alto Offerings Could Land In IPO Investors’ Sweet Spot
Follow-Ons And Other Financings Find Support
Public Company Edition: Kyverna and Alto Neuroscience, which may go public in the US this year, have drug candidates in or nearing mid-stage trials. Also, Zealand’s private placement raises $211.4m, Praxis prices a $150m offering and Solid grosses $108.9m in stock sale.
